{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:28:04Z","timestamp":1792517284643,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001350","name":"Ministry of Health -Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/EDG\/0026\/2008"],"award-info":[{"award-number":["NMRC\/EDG\/0026\/2008"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/CIRG\/1447\/2016"],"award-info":[{"award-number":["NMRC\/CIRG\/1447\/2016"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-000137"],"award-info":[{"award-number":["MOH-000137"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["OFYIRG18may-0021"],"award-info":[{"award-number":["OFYIRG18may-0021"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016477","name":"CareDx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016477","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.trsl.2021.03.019","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T05:47:18Z","timestamp":1617256038000},"page":"48-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Low regulatory T-cells: A distinct immunological subgroup in minimal change nephrotic syndrome with early relapse following rituximab therapy"],"prefix":"10.1016","volume":"235","author":[{"given":"Chang-Yien","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangjian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiong-Huak","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry Yew-Weng","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mya","family":"Than","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley C","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kong-Peng","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kar-Hui","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Kim","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2021.03.019_bib0001","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/ki.1978.23","article-title":"Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. a report of the International Study of Kidney Disease in Children","volume":"13","year":"1978","journal-title":"Kidney int"},{"key":"10.1016\/j.trsl.2021.03.019_bib0002","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fped.2016.00053","article-title":"Long-term outcomes of childhood onset nephrotic syndrome","volume":"4","author":"Hjorten","year":"2016","journal-title":"Front pediatr"},{"key":"10.1016\/j.trsl.2021.03.019_bib0003","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2215\/CJN.05950809","article-title":"Long-term outcome of children with steroid-sensitive idiopathic nephrotic syndrome","volume":"4","author":"Niaudet","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0004","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2021.03.019_bib0005","first-page":"Cd002290","article-title":"Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children","volume":"4","author":"Larkins","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.trsl.2021.03.019_bib0006","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","article-title":"Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes","volume":"97","author":"EYh","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2021.03.019_bib0007","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ki.2013.211","article-title":"Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome","volume":"84","author":"Ravani","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2021.03.019_bib0008","doi-asserted-by":"crossref","first-page":"257","DOI":"10.23876\/j.krcp.2017.36.3.257","article-title":"Long-term repeated rituximab treatment for childhood steroid-dependent nephrotic syndrome","volume":"36","author":"Kim","year":"2017","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.trsl.2021.03.019_bib0009","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10157-020-01938-0","article-title":"Should rituximab be administered before cyclophosphamide as a first-line steroid-sparing agent to young children with steroid-dependent nephrotic syndrome?","volume":"24","author":"Fujinaga","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0010","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s10157-020-01858-z","article-title":"Profound effect of post-rituximab mycophenolate mofetil administration for persistent hypogammaglobulinemia in young children with steroid-dependent nephrotic syndrome","volume":"24","author":"Fujinaga","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0011","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00467-019-04398-1","article-title":"Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome","volume":"35","author":"Parmentier","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0012","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/ndt\/gfu258","article-title":"Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature","volume":"30","author":"Kamei","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trsl.2021.03.019_bib0013","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrneph.2012.289","article-title":"Rituximab therapy in nephrotic syndrome: implications for patients' management","volume":"9","author":"Sinha","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fped.2019.00178","article-title":"Rituximab use in the management of childhood nephrotic syndrome","volume":"7","author":"Kallash","year":"2019","journal-title":"Front pediatr"},{"key":"10.1016\/j.trsl.2021.03.019_bib0015","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semnephrol.2011.06.002","article-title":"Minimal change disease: a CD80 podocytopathy?","volume":"31","author":"Ishimoto","year":"2011","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0016","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3345\/kjp.2016.59.5.205","article-title":"Pathogenesis of minimal change nephrotic syndrome: An immunological concept","volume":"59","author":"Kim","year":"2016","journal-title":"Korean J Pediatr"},{"key":"10.1016\/j.trsl.2021.03.019_bib0017","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1681\/ASN.2006070710","article-title":"Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats","volume":"18","author":"Lai","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0018","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00467-010-1676-x","article-title":"Minimal change disease: a \"two-hit\" podocyte immune disorder?","volume":"26","author":"Shimada","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0019","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2215\/CJN.08500815","article-title":"Anti-CD20 antibodies for idiopathic nephrotic syndrome in children","volume":"11","author":"Ravani","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0020","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1681\/ASN.2015050523","article-title":"B Cell Reconstitution after rituximab treatment in idiopathic nephrotic syndrome","volume":"27","author":"Colucci","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0021","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0022","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/cei.12675","article-title":"Regulatory T cells and minimal change nephropathy: In the midst of a complex network","volume":"183","author":"Bertelli","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0023","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2215\/CJN.11941115","article-title":"T Lymphocyte Activation markers as predictors of responsiveness to rituximab among patients with FSGS","volume":"11","author":"Chan","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0024","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1681\/ASN.2014080799","article-title":"Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial","volume":"26","author":"Ravani","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0025","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10157-010-0330-z","article-title":"Th2 cells predominate in idiopathic steroid-sensitive nephrotic syndrome","volume":"14","author":"Kanai","year":"2010","journal-title":"Clin exp nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0026","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1681\/ASN.V103529","article-title":"Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse","volume":"10","author":"Yap","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0027","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/PL00013437","article-title":"Th1\/Th2 balance and CD45-positive T cell subsets in primary nephrotic syndrome","volume":"14","author":"Stachowski","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0028","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/j.ajkd.2009.03.019","article-title":"Idiopathic nephrotic syndrome and atopy: is there a common link?","volume":"54","author":"Abdel-Hafez","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trsl.2021.03.019_bib0029","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00467-004-1438-8","article-title":"Atopy, serum IgE, and interleukin-13 in steroid-responsive nephrotic syndrome","volume":"19","author":"Cheung","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0030","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/eji.1830250604","article-title":"Involvement of interleukin (IL)-13, but not IL-4, in spontaneous IgE and IgG4 production in nephrotic syndrome","volume":"25","author":"Kimata","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0031","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/tropej\/fmu040","article-title":"Serum immunoglobulin E and interleukin-13 levels in children with idiopathic nephrotic syndrome","volume":"60","author":"Mishra","year":"2014","journal-title":"J Trop Pediatr"},{"key":"10.1016\/j.trsl.2021.03.019_bib0032","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1042\/CS20160312","article-title":"Novel role of Vav1-Rac1 pathway in actin cytoskeleton regulation in interleukin-13-induced minimal change-like nephropathy","volume":"130","author":"Chan","year":"2016","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.trsl.2021.03.019_bib0033","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1042\/CS20190961","article-title":"IL-13-driven alterations in hepatic cholesterol handling contributes to hypercholesterolemia in a rat model of minimal change disease","volume":"134","author":"Low","year":"2020","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.trsl.2021.03.019_bib0034","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaci.2007.11.016","article-title":"Anti-CD20 (rituximab) treatment improves atopic eczema","volume":"121","author":"Simon","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0035","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00467-009-1214-x","article-title":"T regulatory cell function in idiopathic minimal lesion nephrotic syndrome","volume":"24","author":"Araya","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0036","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00467-009-1194-x","article-title":"The prevalence of Th17 cells and FOXP3 regulate T cells (Treg) in children with primary nephrotic syndrome","volume":"24","author":"Shao","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0037","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/ped.13255","article-title":"Regulatory T cells and CTLA-4 in idiopathic nephrotic syndrome","volume":"59","author":"Tsuji","year":"2017","journal-title":"Pediatr Int"},{"key":"10.1016\/j.trsl.2021.03.019_bib0038","first-page":"1","article-title":"Pediatric patients with steroid-sensitive nephrotic syndrome have higher expression of T regulatory lymphocytes in comparison to steroid-resistant disease","volume":"7","author":"Guimar\u00e3es","year":"2019","journal-title":"Front inpediatr"},{"key":"10.1016\/j.trsl.2021.03.019_bib0039","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4103\/0971-4065.132992","article-title":"Regulatory and effector T cells changes in remission and resistant state of childhood nephrotic syndrome","volume":"24","author":"Jaiswal","year":"2014","journal-title":"Ind J Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0040","doi-asserted-by":"crossref","first-page":"3053706","DOI":"10.1155\/2016\/3053706","article-title":"Recent advances in treatments of primary focal segmental glomerulosclerosis in children","volume":"2016","author":"Han","year":"2016","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.trsl.2021.03.019_bib0041","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1681\/ASN.2004070593","article-title":"Focal and segmental glomerulosclerosis: definition and relevance of a partial remission","volume":"16","author":"Troyanov","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 3","key":"10.1016\/j.trsl.2021.03.019_bib0042","first-page":"S11","article-title":"Pathophysiology of minimal change nephrotic syndrome and focal segmental glomerulosclerosis","volume":"12","author":"Cho","year":"2007","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.trsl.2021.03.019_bib0043","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/ki.1990.175","article-title":"Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis","volume":"38","author":"Fogo","year":"1990","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2021.03.019_bib0044","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.coi.2012.12.003","article-title":"T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment","volume":"25","author":"Crespo","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0045","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.coi.2016.09.005","article-title":"T cell exhaustion and immune-mediated disease \u2014 the potential for therapeutic exhaustion","volume":"43","author":"McKinney","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0046","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature14468","article-title":"T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.03.019_bib0047","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/ajkd.2003.50116","article-title":"Steroid-sensitive nephrotic syndrome: from childhood to adulthood","volume":"41","author":"Fakhouri","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trsl.2021.03.019_bib0048","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00467-018-4119-8","article-title":"Childhood onset steroid-sensitive nephrotic syndrome continues into adulthood","volume":"34","author":"Korsgaard","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0049","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.03.019_bib0050","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1111\/ajt.15514","article-title":"Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant","volume":"19","author":"Redfield","year":"2019","journal-title":"Am J Trans"},{"key":"10.1016\/j.trsl.2021.03.019_bib0051","first-page":"71","article-title":"A Phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obinutuzumab or placebo in combination with mycophenolate mofetil in patients with active class III or IV lupus nephritis","author":"Furie","year":"2019","journal-title":"Arthr Rheumatol"},{"key":"10.1016\/j.trsl.2021.03.019_bib0052","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.ekir.2020.06.030","article-title":"Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy","volume":"5","author":"Sethi","year":"2020","journal-title":"Kidney int rep"},{"key":"10.1016\/j.trsl.2021.03.019_bib0053","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","article-title":"Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes","volume":"9","author":"Junttila","year":"2018","journal-title":"Front Immunol"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524421000827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524421000827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:13:52Z","timestamp":1778832832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524421000827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":53,"alternative-id":["S1931524421000827"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2021.03.019","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low regulatory T-cells: A distinct immunological subgroup in minimal change nephrotic syndrome with early relapse following rituximab therapy","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2021.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}